E.I. DuPont de Nemours & Co. (NYSE:DD): Current price $58.41
On Tuesday, DuPont Authentication Inc. announced that it is working jointly with Brother Industries, Ltd. on a worldwide project to help guard its laser and inkjet supplies from illegal counterfeiting. By employing DuPont Izon 3D security holograms in tandem with the DuPont Traceology eVerification system, users may now easily check the authenticity of the Brother supplies they buy. Brother’s anti-counterfeit initiative entails a high-security hologram on supplies packaging, which carries a unique reference number, permitting instant visual authentication and verification that can be completed online or via a mobile application, in-store, at home, or elsewhere.
Merck & Co. (NYSE:MRK): Current price $46.70
Merck and Endocyte Inc. announced Tuesday the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145), which is an investigational folate small molecule drug conjugate, in the Journal of Clinical Oncology, the official journal of the American Society of Clinical Oncology. These trial results form the basis for the vintafolide regulatory application presently under review with the European Medicines Agency for the treatment of folate-receptor positive platinum-resistant ovarian cancer, together with pegylated liposomal doxorubicin.
The Walt Disney Co. (NYSE:DIS): Current price $66.60
Disney has recommended that investors turn down an offer to acquire a small portion of its stock at 4.7 percent below market value. In a statement issued on Tuesday, the Securities and Exchange Commission warned against similar mini-tender offers, which bidders use to “catch investors off guard if the investors do not compare the offer price to the current market price.” The closely held investment firm TRC Capital Corp. made the proposal last week to purchase some 2 million Disney shares for $61 each. TRC has made similar offers this year for share bundles of Intel Corp. and 21st Century Fox Inc.